PROGRAM OVERVIEW
The major depressive disorder (MDD) treatment landscape is evolving, and patients stand to benefit as new evidence is generated and better understood. Johnson & Johnson has invited Drs Roger McIntyre and Andrew Cutler to help interpret two new analyses that add an important perspective to adjunctive treatment considerations. Join this 30‑minute broadcast to hear how these findings may inform clinical practice.
PROGRAM OBJECTIVES
- Review 2 newly published network meta-analyses (NMA) evaluating pharmacologic adjunctive therapies for adults with MDD with inadequate antidepressant response
- Hear directly from NMA authors to contextualize the methodology and outcomes of each study
- Explore how the results of these NMAs can inform adjunctive treatment considerations in clinical practice
Broadcast Schedule
The broadcast will be available at various times throughout the day, depending on your time zone. You can reference the chart below for a complete list of broadcast times. Once registered, you may participate in any of the sessions.
Available via
Tuesday, July 28, 2026
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 12:15 PM | 11:15 AM | 10:15 AM | 9:15 AM |
| 1:15 PM | 12:15 PM | 11:15 AM | 10:15 AM |
| 2:15 PM | 1:15 PM | 12:15 PM | 11:15 AM |
| 3:15 PM | 2:15 PM | 1:15 PM | 12:15 PM |
INTENDED AUDIENCE
This broadcast is intended for US healthcare professionals involved in the treatment of major depressive disorder.
|
© Johnson & Johnson and its affiliates 2026 05/26 US-UNB-2600087 cp-583496v1 |
 |